Jazz Pharmaceuticals PLC (JAZZ)
Days of sales outstanding (DSO)
Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
---|---|---|---|---|---|---|
Receivables turnover | — | — | — | — | — | |
DSO | days | — | — | — | — | — |
December 31, 2024 calculation
DSO = 365 ÷ Receivables turnover
= 365 ÷ —
= —
Based on the provided data, Jazz Pharmaceuticals PLC has not disclosed its days sales outstanding (DSO) for the years 2020 to 2024. This lack of information regarding DSO makes it challenging to assess the efficiency of the company in collecting its accounts receivable and managing its working capital effectively over this period. Monitoring DSO can provide valuable insights into the company's liquidity and potential credit risks. It is important for the management and investors to have access to DSO figures to evaluate the company's financial performance and operational efficiency accurately.
Peer comparison
Dec 31, 2024
Company name
Symbol
DSO
Jazz Pharmaceuticals PLC
JAZZ
—
Abbott Laboratories
ABT
—
AbbVie Inc
ABBV
—
ACADIA Pharmaceuticals Inc
ACAD
—
Alkermes Plc
ALKS
90.15
Amphastar P
AMPH
67.96
ANI Pharmaceuticals Inc
ANIP
—
Arcus Biosciences Inc
RCUS
7.07
Biomarin Pharmaceutical Inc
BMRN
84.73
Bristol-Myers Squibb Company
BMY
81.21
Catalyst Pharmaceuticals Inc
CPRX
—